Brief: MediciNova Announces Results From Phase 2 Trial Of Treatment For Hospitalized COVID-19 Patients At Risk For ARDS

Medicinova

08/06/2022 13:49

June 8 (Reuters) - MediciNova Inc  MNOV.O :
    * MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE
2
CLINICAL TRIAL OF MN-166 (IBUDILAST) IN HOSPITALIZED COVID-19
PATIENTS AT RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME
    * MEDICINOVA INC - TRIAL ACHIEVED STATISTICAL SIGNIFICANCE
FOR ONE
OF CO-PRIMARY ENDPOINTS
    * MEDICINOVA INC - TRIAL ALSO ACHIEVED STATISTICAL
SIGNIFICANCE
FOR PROPORTION OF SUBJECTS DISCHARGED FROM HOSPITAL
    * MEDICINOVA INC - TRIAL ACHIEVED STATISTICAL SIGNIFICANCE
FOR
PROPORTION OF SUBJECTS FREE OF RESPIRATORY FAILURE
    * MEDICINOVA INC - THERE WERE NO SERIOUS ADVERSE EVENTS
RELATED TO
MN-166 (IBUDILAST)
    * MEDICINOVA INC - THERE WERE TWO DEATHS IN PLACEBO GROUP
AND NO
DEATHS IN MN-166 (IBUDILAST) GROUP
    * MEDICINOVA INC - PLAN TO DISCUSS RESULTS OF STUDY WITH FDA
AND
GET FEEDBACK TO DETERMINE NEXT STEPS

Source text for Eikon:  ID:nGNX1fLh00 
Further company coverage:  MNOV.O 

 ((Reuters.Briefs@thomsonreuters.com;))